Embecta faces securities fraud suit after 57% stock drop on insulin pens

Embecta faces a securities fraud class action after its shares plunged 57.8 percent on May 5.

The complaint, filed in the U.S. District Court for the District of New Jersey, alleges Embecta touted the strength of its insulin pen portfolio, telling investors that "prescriptions for insulin pens have been showing a slight positive trend," while in truth the company faced "overall market softness for insulin pens and pen needles."

On May 5, Embecta reported fiscal second-quarter 2026 results that missed guidance, with revenue down more than 14 percent on weakness in pen needle sales. The company said it lost share in its pen needle category, most of it from a single customer, and cut its quarterly dividend to one cent from 15 cents per share. The stock fell $5.35 to close at $3.90, from $9.25 the prior session.

The suit, captioned Apitz-Grossman v. Embecta Corp., covers investors who bought Embecta common stock between Nov. 25, 2025 and May 4, 2026, and asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934. Investors have until Aug. 17 to seek appointment as lead plaintiff.

Embecta, a medical device company spun off from Becton Dickinson in 2022, makes insulin pens and pen needles for patients with diabetes. The complaint alleges the company's guidance was misleading and unattainable because it knew weakness in the U.S. pen needle market was likely to disrupt its revenue outlook and second-quarter results. It also claims Embecta failed to disclose that segment weakness, especially in the U.S. pen needle market, would undermine the guidance it reaffirmed during the class period.

At least four law firms — Bleichmar Fonti & Auld, Schall Brown & Schwartz, Glancy Prongay Wolke & Rotter and DJS Law Group — have announced the action. Embecta competes with Novo Nordisk and Eli Lilly in the broader insulin delivery market, where pen needle demand has softened in the retail channel. The single-customer loss shows the concentration risk in Embecta's pen needle business. The company's admission that the decline in insulin pen prescriptions was "more pronounced in the most recent quarter" came alongside the dividend cut and lowered full-year guidance.

The class action adds legal and reputational risk to a stock already trading near record lows after the dividend cut. The cut to one cent from 15 cents signals Embecta is conserving cash as it navigates the demand slump. Investors will watch whether the company can stabilize pen needle share and whether additional plaintiffs join the case before the Aug. 17 lead plaintiff deadline.

This article is for informational purposes only and does not constitute investment advice.